Neck Pain & Headaches Treatment in Birmingham & Bessemer, AL

Neck Pain & Headache Treatment at Alabama Pain Physicians

Chronic neck pain and headaches are connected more often than most people realize. Cervicogenic headaches — headaches that originate from the neck — are one of the most undertreated conditions in pain medicine. We treat both.

Your treatment plan may include:

• Medical management — muscle relaxants, nerve stabilizers, migraine-specific medications, and anti-inflammatories
• Cervical epidural steroid injections — reducing inflammation around compressed nerves in the neck
• Cervical facet joint injections and medial branch blocks — diagnosing and treating neck joint pain that causes headaches
• Radiofrequency ablation (RF) — long-lasting relief for cervical facet pain and cervicogenic headaches
• Occipital nerve blocks — targeted treatment for occipital neuralgia and migraine
• Botox injections — FDA-approved for chronic migraine, administered by our physicians
• Trigger point injections — for cervical muscle spasm and tension headache
• Medical marijuana certification — for qualifying patients with chronic headache and neck pain

If your headaches haven't responded to over-the-counter medications or your primary care treatments, a pain specialist evaluation may find the source your other doctors have missed.

Understanding Neck Pain & Headaches: A Multi-System Perspective

The following publication by Ty Thomas, MD explores the deeper biological mechanisms behind why neck pain and headaches develop and persist. This research informs how we approach complex and treatment-resistant cases at Alabama Pain Physicians.

Author’s Statement

I am a board-certified Physical Medicine and Rehabilitation physician with additional certification in Venous and Lymphatic Medicine. For over fifteen years at Alabama Pain Physicians, I have managed thousands of patients with chronic pain conditions including cervical radiculopathy, tension-type headache, migraine, cervicogenic headache, and occipital neuralgia. The consistent observation that drives this publication series is the limited, partial treatment response that characterizes conventional management of neck pain and headache across all modalities. Topiramate prevents migraine in roughly one out of four patients beyond placebo, but produces cognitive impairment, paresthesia, and metabolic acidosis. CGRP monoclonal antibodies — the most targeted migraine therapy ever developed — fail to produce meaningful improvement in approximately forty percent of patients. Cervical epidural steroid injections provide weeks of relief, then the pain returns. These partial responses are not clinical failures in the traditional sense — each intervention does what it is designed to do. They are evidence that the interventions are addressing only one component of a multi-component problem.

This observation led me to cellular systems biology as a framework for understanding the clinical entities I encounter daily. Neck pain and headache are particularly instructive because they share cervical spine anatomy, trigeminocervical neurology, and — critically — the same upstream metabolic, inflammatory, hormonal, and microbiome domains that conventional medicine rarely evaluates. I have spent years developing assessment protocols, building laboratory infrastructure through CLIA-certified laboratories, and studying the biological pathways that connect these domains. I own clinics, laboratories, and value-based care companies with the goal of providing patients better outcomes. Better outcomes require questioning our current understanding and applying different conceptual frameworks to better explain pathology and wellness.

These publications are my attempt to provide information about this understanding — how common clinical manifestations of pain can be explained, diagnosed, and treated through cellular systems analysis. They are not a claim to have found a root cause. They are a framework for asking better questions.

Abstract

Background

Neck pain affects an estimated 203 million people globally, with projections reaching 269 million by 2050 (GBD 2021 Neck Pain Collaborators, Lancet Rheumatology, 2024). Migraine is the second leading cause of years lived with disability worldwide, affecting approximately 15% of the global population (Steiner et al., Journal of Headache and Pain, 2020). Direct medical costs for low back and neck pain combined exceed $134.5 billion annually in the United States (Dieleman et al., JAMA, 2020). Current treatment approaches target individual mechanisms: topiramate modulates sodium channels and GABA for migraine prevention (NNT 4; Linde et al., Cochrane Database of Systematic Reviews, 2013), CGRP monoclonal antibodies block calcitonin gene-related peptide signaling (approximately 60% achieve ≥50% reduction in monthly migraine days; Barbanti et al., Journal of Neurology, 2024), and cervical epidural steroid injections suppress perineural inflammation. These limited response rates suggest that single-pathway interventions are insufficient for conditions involving multiple biological systems.

Methods

We conducted a narrative review of PubMed-indexed literature examining neck pain and headache through cellular systems theory, which proposes that these conditions emerge from dynamic interactions across seven biological domains. We reviewed evidence for metabolic, mitochondrial, inflammatory, neuroendocrine, microbiome, vascular, and structural domain involvement in cervical pain, migraine, tension-type headache, and cervicogenic headache. We analyzed treatment response data for conventional interventions and constructed composite clinical scenarios illustrating individualized multi-domain assessment and intervention.

Results

Published evidence demonstrates that neck pain and headache involve dysfunction across multiple biological domains: insulin resistance is significantly associated with migraine, with hyperinsulinemia in the highest quartile conferring a 5.7-fold increased risk (Gruber et al., Cephalalgia, 2010); metabolic syndrome is present in approximately 32% of migraineurs (Bhoi et al., Journal of Headache and Pain, 2012); migraine is associated with intestinal dysbiosis, increased gut permeability, and systemic inflammation (systematic reviews, 2024–2026); metabolic syndrome components are associated with disc degeneration across the entire spine including the cervical region (Teraguchi et al., PLoS One, 2016); and the trigeminocervical complex provides a neuroanatomical substrate through which cervical and cranial pain generators share the same processing pathways.

Conclusions

The pattern of multi-domain biological dysfunction combined with limited, partial response to single-pathway treatments supports the hypothesis that neck pain and headache represent multi-system cellular disorders requiring individualized, domain-specific intervention. Cellular systems theory provides a framework for identifying which domains are dysfunctional in each patient and directing treatment accordingly.

1. Introduction

Neck pain and headache are among the most prevalent and disabling conditions in clinical medicine. Neck pain affected an estimated 203 million people globally in 2020, with age-standardized prevalence higher in women than men and projected case numbers reaching 269 million by 2050 (GBD 2021 Neck Pain Collaborators, Lancet Rheumatology, 2024). Migraine ranks as the second leading cause of years lived with disability worldwide, first among young women (Steiner et al., Journal of Headache and Pain, 2020). In the United States, migraine affects approximately 20% of the population (Burch et al., Headache, 2018), and direct medical costs for low back and neck pain combined exceed $134.5 billion annually (Dieleman et al., JAMA, 2020). These conditions are frequently treated by separate specialists — the pain physician manages the neck, the neurologist manages the headache — as though they arise from unrelated pathologies.

Yet neck pain and headache are neuroanatomically inseparable. The trigeminocervical complex — the convergence zone where sensory fibers from the upper cervical nerve roots (C1–C3) and the trigeminal nerve share second-order neurons in the trigeminal nucleus caudalis — means that cervical pathology can generate head pain, and cranial pain generators can produce neck symptoms (Bogduk, Cephalalgia, 2001). This convergence explains cervicogenic headache, the overlap of migraine with neck pain, and why patients so commonly present with both simultaneously. It also means that the biological domains driving cervical degeneration are the same domains contributing to headache pathophysiology.

The prevailing clinical model treats neck pain as a structural-mechanical problem requiring imaging-guided intervention, and headache as a neurovascular or neurotransmitter disorder requiring pharmacotherapy. This separation is logical, evidence-based for acute intervention, and frequently effective in the short term. However, the long-term clinical performance of these single-pathway approaches challenges their sufficiency.

Cellular systems theory proposes that neck pain and headache emerge from the dynamic interaction of metabolic, inflammatory, hormonal, vascular, microbiome, and structural domains that conventional medicine evaluates in isolation. The cervical disc does not degenerate in a vacuum. The trigeminal system does not become sensitized without provocation. The migraine does not chronify without a biological environment that supports chronification. When that biological environment is dysfunctional across multiple domains simultaneously, single-pathway interventions cannot produce sustained improvement because the biological conditions that caused the damage — and that prevent its repair — remain active.

2. Methods

We conducted a narrative review of PubMed-indexed literature examining biological domain dysfunction in chronic neck pain and headache. Search terms included neck pain, cervical pain, cervical disc degeneration, cervical radiculopathy, cervicogenic headache, migraine, tension-type headache, chronic migraine, CGRP, trigeminocervical complex combined with insulin resistance, metabolic syndrome, neuroinflammation, neurogenic inflammation, NF-κB, mast cell, HPA axis, cortisol, microbiome, gut-brain axis, intestinal permeability, oxidative stress, mitochondrial dysfunction, serotonin, magnesium, and treatment response. We included systematic reviews, meta-analyses, randomized controlled trials, Mendelian randomization studies, and large population-based cohort studies. We analyzed treatment response data from systematic reviews of conventional neck pain and headache interventions. We constructed composite clinical scenarios to illustrate individualized multi-domain assessment and intervention.

3. The Limitations of Single-Pathway Treatment

3.1 Migraine Preventive Pharmacotherapy

Topiramate, one of the most widely prescribed migraine preventive agents, has a number needed to treat of 4 for at least 50% reduction in headache frequency in a Cochrane review of 17 randomized controlled trials with 2,282 patients (Linde et al., Cochrane Database of Systematic Reviews, 2013). However, adverse effects are common and often treatment-limiting: paresthesia (NNH 2–3), cognitive impairment including difficulty with memory, concentration, and word-finding (NNH 12–25), fatigue (NNH 12–25), and metabolic acidosis in 10% of patients. Topiramate causes weight loss rather than weight gain, which distinguishes it metabolically from other preventives, but its cognitive effects directly impair quality of life and functional capacity. It also inhibits carbonic anhydrase, promoting renal calculi and metabolic acidosis — effects that do not address any domain driving the headache.

Valproate has an NNT of 5 for at least 50% reduction in migraine frequency (Linde et al., Cochrane Database of Systematic Reviews, 2013), but causes tremor, nausea, weight gain, and is teratogenic. Weight gain from valproate worsens insulin resistance — the metabolic condition increasingly associated with migraine chronification. Beta-blockers including propranolol provide comparable migraine prevention but cause fatigue, exercise intolerance, and weight gain, removing the patient’s ability to exercise — itself one of the most effective metabolic interventions for migraine.

CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) represent the first migraine-specific preventive therapy. Approximately 60% of treated patients achieve at least 50% reduction in monthly migraine days at 12 weeks (Barbanti et al., Journal of Neurology, 2024). This means roughly 40% of patients do not respond meaningfully. NNTs range from 3 for eptinezumab to 6 for erenumab in treatment-refractory patients. While superior in tolerability to older preventives, CGRP antibodies target a single neuropeptide pathway. They do not address insulin resistance, gut dysbiosis, hormonal fluctuations, sleep disruption, or the systemic inflammatory environment that may be driving trigeminal sensitization. Constipation — a recognized CGRP antibody side effect (Holzer and Holzer-Petsche, Frontiers in Physiology, 2021) — may worsen gut barrier function in patients with active microbiome domain dysfunction.

3.2 Acute Migraine Treatment

Triptans are effective for acute migraine attacks but do not prevent future attacks. Medication overuse headache develops in approximately 1–2% of the general population and up to 50% of patients in headache clinics (Westergaard et al., Journal of Headache and Pain, 2014), creating a cycle in which the treatment for headache produces more headache. This iatrogenic transformation from episodic to chronic headache is a direct consequence of single-pathway acute treatment without addressing the upstream biology driving attack frequency.

3.3 Cervical Pain Interventions

Cervical epidural steroid injections and cervical medial branch blocks follow the same pattern documented in the companion low back pain publication (Thomas, Alabama Pain Physicians, 2026): short-term benefit with limited evidence for long-term efficacy. Cervical facet radiofrequency ablation provides meaningful relief for 3–9 months but does not address why the facet joint became arthritic or inflamed. Cervical disc degeneration follows the same asymptomatic prevalence pattern as lumbar degeneration — present in a majority of asymptomatic individuals on MRI by middle age (Brinjikji et al., AJNR, 2015) — demonstrating that structural pathology alone does not explain who develops pain.

3.4 Synthesis: The Pattern of Partial Response

Across all modalities, the treatment response data reveal a consistent pattern. Topiramate helps roughly one in four patients beyond placebo but produces cognitive and metabolic side effects. CGRP antibodies fail to help approximately 40% of patients. Cervical interventions provide short-term structural relief without addressing biology. Triptans can produce the very condition they treat. This pattern is predicted by a multi-domain disorder being treated with single-domain interventions. If neck pain and headache involve variable dysfunction across metabolic, inflammatory, hormonal, microbiome, vascular, and structural domains, then a single-mechanism agent would be expected to help only the subset of patients in whom that mechanism is the dominant driver. The limited response rates are evidence that the interventions are incomplete.

4. Evidence for Multi-Domain Dysfunction in Neck Pain and Headache

4.1 Mitochondrial Function and Metabolic Dysfunction

Insulin resistance is significantly associated with migraine. Hyperinsulinemia in the highest quartile confers a 5.7-fold increased risk of migraine compared with the lowest quartile (Gruber et al., Cephalalgia, 2010). Metabolic syndrome is present in approximately 32% of migraineurs, correlating with longer headache duration and multiple triggers (Bhoi et al., Journal of Headache and Pain, 2012). Chronic migraine in women is specifically associated with insulin resistance as measured by HOMA-IR (Fava et al., European Journal of Neurology, 2014). Brain insulin resistance has been proposed as a mechanism for migraine chronification through impaired neuronal glucose uptake, triggering the energy deficit that provokes cortical spreading depression — the wave of neural depolarization that underlies migraine aura and activates the trigeminovascular system (Cavestro et al., Journal of Pain, 2022).

The mechanisms connecting insulin resistance to both headache and cervical degeneration operate through shared pathways. Advanced glycation end products (AGEs) from chronically elevated blood sugar cross-link collagen in cervical discs, stiffening the matrix and impairing nutrient diffusion. NF-κB activation from insulin resistance drives inflammatory cytokine production that sensitizes the trigeminal system and accelerates disc breakdown (Niederberger and Geisslinger, FASEB Journal, 2008). Metabolic syndrome components are associated with disc degeneration across the entire spine including the cervical region (Teraguchi et al., PLoS One, 2016). The relationship between pain and insulin resistance is bidirectional (Zhai et al., Journal of Pain, 2016), meaning that untreated neck pain and chronic headache can worsen the metabolic environment that is driving them.

4.2 Immune Surveillance and Inflammation

Migraine pathophysiology involves neurogenic inflammation — the release of inflammatory neuropeptides including CGRP and substance P from trigeminal nerve endings in the meninges, producing vasodilation, plasma protein extravasation, and mast cell degranulation. This neurogenic inflammation is not a random event: it occurs in the context of a trigeminal system that has been sensitized by systemic inflammatory signals. Systemic markers of inflammation including TNF-α, IL-6, and C-reactive protein are elevated in migraineurs compared to controls, both during attacks and interictally (Perini et al., Headache, 2005). Mast cells in the dura mater degranulate in response to CGRP and substance P, releasing histamine and additional inflammatory mediators that further sensitize trigeminal afferents.

Central sensitization — the amplification of pain signals within the spinal cord and brainstem — contributes to both chronic headache and chronic neck pain through glial cell activation and enhanced synaptic transmission in the trigeminocervical complex (Woolf, Pain, 2011; Watkins and Maier, Physiological Reviews, 2002). The cervical spine and the head share this processing center, which is why systemic inflammatory priming from any source — metabolic, gut-derived, or adipose-driven — can amplify both cervical and cranial pain simultaneously.

4.3 Neuroendocrine Regulation

Hormonal fluctuations are among the most powerful triggers for migraine. Estrogen withdrawal during the late luteal phase triggers menstrual migraine in approximately 60% of women with migraine, through mechanisms including CGRP sensitization and reduced serotonin receptor density (MacGregor, Nature Reviews Neurology, 2012). This hormonal influence explains the female predominance of migraine (3:1 female to male ratio) and the changes in migraine patterns at menarche, pregnancy, perimenopause, and menopause.

Sleep disruption independently predicts chronic pain development and is bidirectionally linked to both headache and neck pain (Finan et al., Journal of Pain, 2013; Choy, Nature Reviews Rheumatology, 2015). Poor sleep quality is among the most consistent migraine triggers reported by patients. HPA axis dysregulation — particularly the wired-tired pattern of cortisol overactivation progressing to cortisol depletion — contributes to both headache chronification and cervical pain amplification (Heim et al., Psychoneuroendocrinology, 2000). Anxiety and depression, mediated through HPA axis dysfunction, are comorbid in approximately 40–50% of patients with chronic migraine.

4.4 Microbiome and Mucosal Immunity

Migraine has been associated with intestinal dysbiosis, increased gut permeability, and low-grade systemic inflammation in multiple systematic reviews (systematic reviews in Journal of Headache and Pain, 2025; Nutrients, 2023; Neurobiology of Pain, 2022). Irritable bowel syndrome co-occurs in up to 50% of patients with migraine. Mendelian randomization studies support a causal association between specific gut microbiota composition and migraine risk. Gut barrier dysfunction allows bacterial lipopolysaccharide (LPS) to translocate into systemic circulation, activating NF-κB-mediated inflammatory cascades that sensitize the trigeminovascular system (Camilleri, Gut, 2019). Gut dysbiosis alters tryptophan metabolism, reducing serotonin availability — directly relevant because serotonin depletion is a central mechanism in migraine pathophysiology and descending pain inhibition.

Gastrointestinal symptoms are prominent in migraine: nausea and vomiting occur in 60–95% and 50–62% of patients during attacks, respectively. These are not incidental symptoms but reflect the gut-brain axis dysfunction that may be driving the headache itself. Medications used to treat migraine — including NSAIDs, triptans, and CGRP antibodies (which cause constipation) — can all worsen gut barrier function, potentially accelerating the gut-immune-brain cascade in treated patients.

4.5 Detoxification and Oxidative Stress

Mitochondrial dysfunction and oxidative stress have been documented in migraine. Elevated markers of oxidative stress are found in migraineurs, and mitochondrial supplements including CoQ10, riboflavin (vitamin B2), and magnesium have demonstrated modest efficacy in migraine prevention — suggesting that mitochondrial energy failure contributes to the attack threshold (Gross et al., Cephalalgia, 2019). Environmental toxic burden including heavy metals may contribute to neuroinflammatory tone, though the evidence base for direct headache-specific toxicity is limited.

4.6 Vascular Integrity

Migraine has long been associated with vascular pathology, though the purely vascular theory has been superseded by the neurovascular model. Endothelial dysfunction is documented in migraineurs and may contribute to the vascular phase of the attack (Vanmolkot and de Haan, Cephalalgia, 2007). Migraineurs, particularly those with aura, have increased cardiovascular risk including elevated rates of stroke and myocardial infarction, suggesting shared endothelial and metabolic pathology. In the cervical spine, endothelial dysfunction compromises the vascular supply to cervical discs and nerve roots, connecting the vascular domain to cervical structural degeneration through the same mechanisms documented in the companion low back pain publication (Thomas, Alabama Pain Physicians, 2026).

4.7 Structural Domain: The Trigeminocervical Convergence

The trigeminocervical complex provides the neuroanatomical substrate through which cervical structural pathology produces headache and cranial sensitization produces neck pain (Bogduk, Cephalalgia, 2001). Cervicogenic headache — headache arising from cervical sources — is clinically underrecognized and frequently misdiagnosed as migraine or tension-type headache. Cervical facet arthropathy, disc degeneration, and myofascial dysfunction in the upper cervical spine can generate referred pain to the occiput, temple, and frontal regions through the convergent trigeminocervical pathways.

Cervical disc degeneration, like lumbar disc degeneration, is nearly universal in asymptomatic populations by middle age (Brinjikji et al., AJNR, 2015). The structural finding alone does not explain who develops pain. Cellular systems theory proposes that the metabolic, inflammatory, hormonal, and vascular environment determines whether a given degree of cervical degeneration becomes symptomatic — and whether that structural pathology produces isolated neck pain, referred headache, or both.

5. Inter-Domain Cascade Mechanics

5.1 The Metabolic-Inflammatory-Trigeminovascular Cascade

Insulin resistance (Gruber et al., 2010; Fava et al., 2014) promotes neurogenic inflammation through multiple converging pathways. Hyperinsulinemia sensitizes CGRP signaling in trigeminal neurons, lowering the threshold for cortical spreading depression and migraine initiation. NF-κB activation from insulin resistance (Niederberger and Geisslinger, 2008) drives systemic inflammatory cytokine production that primes the trigeminovascular system. Visceral adipose tissue produces TNF-α and IL-6 that cross the blood-brain barrier and sensitize meningeal nociceptors. Simultaneously, the same metabolic dysfunction damages cervical disc collagen through AGE accumulation and promotes cervical facet inflammation through systemic inflammatory tone. The result is a patient with both chronic headache and chronic neck pain arising from the same upstream metabolic pathology. Topiramate can reduce migraine frequency through sodium channel and CGRP modulation but cannot reverse the insulin resistance, the neuroinflammatory priming, or the cervical disc degeneration. CGRP antibodies block one neuropeptide without addressing the metabolic environment that sensitized the CGRP pathway.

5.2 The Gut-Brain-Trigeminovascular Cascade

Gut barrier dysfunction (Camilleri, 2019) produces systemic LPS translocation and NF-κB-mediated inflammation. This systemic inflammatory tone activates glial cells in the trigeminocervical complex, promoting central sensitization (Watkins and Maier, 2002; Woolf, 2011). Gut dysbiosis alters tryptophan metabolism, reducing serotonin availability and weakening descending pain inhibition — directly lowering the migraine threshold. IBS co-occurring in up to 50% of migraineurs is not coincidental but reflects shared gut-brain axis dysfunction. NSAID use for headache damages the gut mucosa. Triptan overuse can worsen gastric motility. CGRP antibodies cause constipation through antagonism of CGRP’s motor-stimulating function in the intestine. Each single-pathway headache treatment can worsen the gut domain that is driving headache chronification.

5.3 The Sleep-Hormone-Cervical Cascade

Sleep disruption (Finan et al., 2013; Choy, 2015) reduces deep sleep-dependent growth hormone release, impairing cervical disc repair and collagen maintenance. Estrogen fluctuations sensitize the trigeminovascular system, producing menstrual migraine and contributing to the female predominance of chronic headache. HPA axis overactivation from chronic pain-related stress (Heim et al., 2000) produces cortisol abnormalities that impair tissue repair and promote inflammatory disinhibition. Low testosterone reduces anabolic capacity for both cervical structural repair and neuronal maintenance. The structural damage from the metabolic-inflammatory cascade cannot be repaired because the hormonal environment required for repair is itself dysfunctional. Standard pharmacological sleep aids often suppress deep sleep stages rather than restoring them, potentially worsening this cascade.

5.4 The Cervicogenic-Migraine Convergence

The trigeminocervical complex means that cervical structural dysfunction and migraine are not separate conditions in separate anatomical compartments. They converge on the same neural processing center. A patient with metabolic-inflammatory cervical disc degeneration and a gut-immune-driven migraine susceptibility has both conditions amplifying each other through shared second-order neurons. The cervical pathology lowers the migraine threshold. The migraine sensitization amplifies the cervical pain. This convergence explains why so many headache patients have neck pain and why treating one without the other produces incomplete results.

6. Clinical Scenarios: Individualized Domain Assessment

The following composite clinical scenarios illustrate how cellular systems theory guides individualized assessment and intervention for neck pain and headache. All laboratory values represent plausible clinical findings consistent with the domain dysfunction documented in the cited studies.

6.1 Patient A: Metabolic-Inflammatory Chronic Migraine

Presentation: 45-year-old woman, BMI 32, with 15-year history of episodic migraine that has progressed to chronic migraine (18 headache days per month) over the past 3 years. Also reports bilateral neck pain and stiffness. Cervical MRI shows moderate multilevel disc desiccation and mild facet arthropathy C4–C6. Failed trials of topiramate (cognitive side effects), propranolol (fatigue, weight gain), and amitriptyline (weight gain, morning sedation). Currently on erenumab 140 mg monthly with modest improvement (18 reduced to 12 headache days). Pain 7/10. Sleep 5 hours per night.

Domain Assessment — Laboratory Findings: Fasting insulin 24 µIU/mL (elevated; reference <10), HbA1c 6.1% (prediabetic), HOMA-IR 5.8 (elevated). hs-CRP 4.8 mg/L (elevated). Total testosterone 14 ng/dL (low). DHEA-S low. TSH 4.2 mIU/L with low-normal free T3 (subclinical hypothyroid pattern). Vitamin D 19 ng/mL (deficient). Omega-3 index 2.4% (critically low). RBC magnesium low. Vitamin B2 (riboflavin) low-normal.

Domain Interpretation: This patient demonstrates the metabolic-inflammatory-trigeminovascular cascade. Severe insulin resistance is driving neurogenic inflammation through CGRP sensitization, NF-κB activation, and adipose-derived cytokine production. The prediabetic metabolic profile is simultaneously accelerating her cervical disc degeneration. Markedly elevated hs-CRP confirms systemic inflammation. Low testosterone, low DHEA-S, and subclinical hypothyroidism represent neuroendocrine domain exhaustion, removing anti-inflammatory hormonal braking and tissue repair capacity. Severely deficient vitamin D, critically low omega-3, and low magnesium each independently contribute to migraine threshold lowering. Previous treatments either caused weight gain (worsening insulin resistance), cognitive impairment, or addressed only the CGRP pathway without modifying any upstream driver. Erenumab reduced headache days from 18 to 12 — meaningful but incomplete — because the metabolic and inflammatory drivers remain active.

Individualized Protocol: Metabolic optimization: anti-inflammatory dietary protocol guided by continuous glucose monitoring, targeting insulin sensitization. Graded exercise program emphasizing Zone 2 cardiovascular training. Thyroid optimization. Testosterone and DHEA guided by endocrine assessment. Vitamin D repletion to 50–80 ng/mL. Omega-3 repletion to index >8%. Magnesium repletion (glycinate form). Riboflavin 400 mg daily. MOTS-c (5–10 mg SC three times weekly, morning) targeting AMPK activation and insulin sensitization (Lee et al., Cell Metabolism, 2015). BPC-157 (250–500 µg orally twice daily) for gut barrier support and nitric oxide restoration (Gwyer et al., Cell and Tissue Research, 2019). Selank (250–500 µg SC two to three times daily) for HPA axis modulation without cognitive impairment (Zozulia et al., Zhurnal Nevrologii i Psikhiatrii, 2008). DSIP (100–200 µg SC at bedtime) for deep sleep restoration and growth hormone release. Continue erenumab during metabolic optimization. Reassessment of metabolic markers, inflammatory markers, hormonal panel, and headache diary at 12 weeks.

6.2 Patient B: Gut-Immune-Neuroendocrine Cervicogenic Pattern

Presentation: 34-year-old woman with 3-year history of unilateral right-sided headache originating from the occipital region, radiating to the right temple. Associated bilateral neck stiffness. Reports bloating, food sensitivities, and anxiety (7/10). Cervical MRI shows mild C2–C3 disc desiccation and right C2–C3 facet arthropathy. Pain is disproportionate to imaging. Upper cervical facet block provided 4 weeks of significant relief confirming cervicogenic component. Gabapentin 600 mg TID provides minimal benefit and causes cognitive fog. Pain 6/10.

Domain Assessment — Laboratory Findings: Fasting insulin 9 µIU/mL (normal). HbA1c 5.0% (normal). hs-CRP 2.6 mg/L (mildly elevated). Elevated evening cortisol with loss of normal diurnal decline. Positive SIBO breath test (hydrogen-dominant). Elevated zonulin (intestinal permeability marker). Microbiome analysis showing reduced diversity with depleted Lactobacillus and Bifidobacterium. Vitamin D 27 ng/mL (suboptimal). B12 normal. Hormonal panel otherwise unremarkable.

Domain Interpretation: This patient demonstrates the gut-immune-cervicogenic convergence. Normal metabolic markers exclude insulin resistance as the primary driver. The unilateral headache with confirmed cervicogenic component localizes the structural source to the upper cervical facet. However, the pain disproportionate to imaging suggests central sensitization (Woolf, 2011). Positive SIBO and elevated zonulin confirm gut barrier dysfunction feeding systemic inflammation through LPS translocation (Camilleri, 2019). The gut-immune-brain cascade is sensitizing the trigeminocervical complex, amplifying what would otherwise be manageable cervicogenic input. Elevated evening cortisol reflects HPA axis overactivation. Gabapentin addresses calcium channel modulation without addressing the gut-driven inflammatory sensitization.

Individualized Protocol: SIBO treatment per established protocols. Oral BPC-157 (250–500 µg twice daily) for gut barrier restoration (Gwyer et al., 2019). KPV (200–400 µg orally twice daily) targeting NF-κB inhibition at the gut mucosal level. Elimination dietary protocol. Selank (250–500 µg SC two to three times daily) for anxiety and HPA axis modulation (Zozulia et al., 2008). Semax (200–600 µg SC daily) for BDNF enhancement and cognitive support. Vitamin D optimization. Upper cervical radiofrequency ablation for structural symptomatic control during biological optimization. Manual therapy and postural rehabilitation for cervical component. Reassessment of SIBO, intestinal permeability, inflammatory markers, and cortisol curve at 12 weeks.

6.3 Patient C: Structural-Hormonal-Vascular Cervical Pattern

Presentation: 56-year-old woman, 4 years postmenopausal, with progressive neck pain and bilateral arm numbness over 2 years. Intermittent occipital headaches. Cervical MRI shows multilevel disc degeneration C4–C7 with moderate central stenosis at C5–C6 and bilateral foraminal narrowing C5–C6 and C6–C7. Previous anterior cervical discectomy and fusion C5–C6 eighteen months ago provided 8 months of improvement followed by recurrence of symptoms at adjacent levels. Pain 7/10. Considering revision surgery.

Domain Assessment — Laboratory Findings: Fasting insulin 16 µIU/mL (mildly elevated). HbA1c 5.7% (upper normal). hs-CRP 3.8 mg/L (elevated). Estradiol <12 pg/mL (postmenopausal). Total testosterone 10 ng/dL (low). DHEA-S markedly low. IGF-1 low-normal. Vitamin D 22 ng/mL (deficient). Omega-3 index 3.0% (critically low). Organic acids showing markers consistent with impaired mitochondrial function and elevated methylmalonic acid (functional B12 insufficiency).

Domain Interpretation: This patient demonstrates the structural-hormonal-vascular cascade producing adjacent segment disease after surgery. Postmenopausal estrogen decline accelerates cervical disc degeneration through loss of estrogen’s anti-inflammatory and disc-protective effects. Low testosterone and DHEA-S remove anabolic support for connective tissue. Low IGF-1 suggests growth hormone insufficiency impairing tissue repair. Mild insulin resistance and elevated hs-CRP confirm metabolic-inflammatory contribution. Functional B12 insufficiency impairs methylation and myelin maintenance. Her prior ACDF corrected the structural stenosis at C5–C6 but did not address the hormonal depletion, metabolic dysfunction, or inflammatory environment driving multilevel degeneration. Adjacent segment disease is the expected outcome when the biology producing degeneration remains active.

Individualized Protocol: Hormonal optimization: estradiol, testosterone, and DHEA replacement guided by endocrine assessment. Vitamin D repletion. B12 repletion (methylcobalamin form). Omega-3 repletion. Anti-inflammatory dietary protocol. MOTS-c (5–10 mg SC three times weekly) for metabolic optimization (Lee et al., 2015). GHK-Cu (1–2 mg SC daily) for collagen and glycosaminoglycan stimulation and gene expression modulation toward repair (Pickart and Margolina, BioMed Research International, 2014; Pickart et al., International Journal of Molecular Sciences, 2018). TB-500 (750 µg to 1.5 mg SC twice weekly) for tissue remodeling with anti-fibrotic properties (Malinda et al., Journal of Investigative Dermatology, 1999). Ipamorelin/CJC-1295 at bedtime for growth hormone restoration. NAD+ (IV 250–500 mg 1–2x weekly for loading) for mitochondrial energy substrate. Interventional management for symptomatic control during biological optimization. Defer revision surgery pending 6-month reassessment.

7. Emerging Peptide Therapeutics: Domain-Targeted Intervention

Peptide therapeutics offer potential for domain-targeted intervention in neck pain and headache. The following peptides have published evidence connecting their mechanisms to biological domains documented as dysfunctional in these conditions. No randomized controlled trials of these peptides for neck pain or headache as primary indications have been published; evidence is extrapolated from mechanism-of-action studies and trials in related conditions.

Selank modulates GABA through allosteric GABAA receptor mechanisms to reduce anxiety without sedation, dependence, or cognitive impairment. In a clinical study of 62 patients with generalized anxiety disorder, anxiolytic effect was comparable to benzodiazepine medazepam with additional antiasthenic effects (Zozulia et al., Zhurnal Nevrologii i Psikhiatrii, 2008; Kasian et al., Frontiers in Pharmacology, 2017). Addresses the anxiety and HPA axis overactivation component of chronic headache without the cognitive or metabolic side effects of topiramate, valproate, or antidepressants. Subcutaneously at 250–500 µg two to three times daily. Not FDA-approved in the United States.

Semax increases brain-derived neurotrophic factor (BDNF), enhancing neuroplasticity and supporting neuronal resilience. Approved in Russia for stroke recovery. Relevant to headache through BDNF’s role in modulating central sensitization and trigeminal plasticity. Subcutaneously or intranasally at 200–600 µg two to three times daily. Not FDA-approved in the United States.

MOTS-c activates AMPK to improve insulin sensitivity, reduce inflammatory cytokines, and promote metabolic homeostasis (Lee et al., Cell Metabolism, 2015). Targets the insulin resistance increasingly documented as associated with migraine susceptibility and cervical disc degeneration. Subcutaneously at 5–10 mg three times weekly in the morning. Not FDA-approved.

BPC-157 restores gut barrier integrity, reduces intestinal inflammation, restores nitric oxide production in blood vessel walls, and has demonstrated nerve regeneration in preclinical models (Gwyer et al., Cell and Tissue Research, 2019; Gjurasin et al., Regulatory Peptides, 2010). Its primary relevance to headache is the gut-immune-brain cascade, targeting the upstream gut barrier dysfunction that feeds systemic neuroinflammation. Orally at 250–500 µg twice daily. Not FDA-approved.

KPV directly inhibits NF-κB without suppressing overall immune function, concentrating preferentially in gastrointestinal mucosa. Targets the inflammatory amplification pathway at the gut level. Orally at 200–400 µg twice daily. Not FDA-approved.

DSIP promotes delta-wave deep sleep architecture rather than forcing sedation. Targets the sleep-hormone-repair cascade by restoring the sleep stage during which growth hormone release, tissue repair, and inflammatory resolution occur (Choy, 2015; Finan et al., 2013). Subcutaneously at 100–200 µg at bedtime. Not combined with benzodiazepines. Not FDA-approved.

GHK-Cu stimulates collagen, elastin, and glycosaminoglycan production, and modulates approximately 32% of human gene expression toward repair patterns (Pickart and Margolina, 2014; Pickart et al., 2018). Relevant for cervical disc and connective tissue repair. Subcutaneously 1–2 mg daily. Not FDA-approved.

TB-500 promotes cell migration to injured tissue and anti-fibrotic tissue remodeling (Malinda et al., 1999). Relevant for cervical structural repair. Subcutaneously 750 µg to 1.5 mg twice weekly. Not FDA-approved.

SS-31 (elamipretide) stabilizes the inner mitochondrial membrane by binding cardiolipin, improving bioenergetic efficiency (Szeto, 2014; Birk et al., 2013; Karaa et al., 2018). Relevant to the mitochondrial dysfunction documented in migraine. Subcutaneously at 5–10 mg daily. Not FDA-approved for pain indications.

Peptide protocols are individualized based on domain assessment findings. The clinical scenarios in Section 6 illustrate how peptide selection is directed by laboratory data rather than applied as a standardized protocol. Additional peptides targeting immune regulation, detoxification, and hormonal restoration may be indicated based on individual assessment.

8. Discussion

The evidence reviewed in this paper supports three propositions. First, neck pain and headache involve measurable dysfunction across multiple biological domains, not merely structural cervical pathology or isolated neurovascular dysfunction. Insulin resistance, systemic inflammation, gut dysbiosis, hormonal fluctuations, HPA axis dysregulation, oxidative stress, and endothelial dysfunction have each been independently documented in association with migraine, chronic headache, and cervical pain conditions.

Second, the limited, partial response to single-pathway treatments is consistent with a multi-domain disorder. When topiramate helps one in four patients beyond placebo, when CGRP antibodies fail 40% of patients, and when cervical interventions provide short-term but not durable relief, the data are not showing that these interventions are ineffective. They are showing that these interventions address only one component of a multi-component problem. The near-universal prevalence of cervical disc degeneration in asymptomatic populations (Brinjikji et al., 2015) demonstrates that structural pathology alone cannot explain who develops cervical pain or cervicogenic headache.

Third, conventional treatments can actively worsen domains they do not target. Valproate and beta-blockers cause weight gain that worsens insulin resistance. Topiramate produces cognitive impairment. NSAIDs damage gut mucosa. Triptans overuse produces medication overuse headache. CGRP antibodies cause constipation. Opioids suppress the HPA axis, reduce testosterone, disrupt sleep, and impair gut function. These destabilizing effects help explain why chronic headache and chronic neck pain are often progressive conditions despite ongoing treatment.

The trigeminocervical complex provides the neuroanatomical basis for understanding why neck pain and headache must be evaluated together rather than as separate diagnostic categories. The convergence of cervical and trigeminal afferents on shared brainstem neurons means that the same biological environment — the same metabolic dysfunction, the same inflammatory tone, the same hormonal deficiency, the same gut-derived immune activation — drives both conditions simultaneously. Treating the headache without evaluating the cervical spine, or treating the cervical spine without asking why it degenerated, produces the pattern of incomplete response that characterizes conventional management.

Limitations include the narrative methodology, the observational nature of key metabolic-migraine studies, the preclinical basis of most peptide evidence, and the absence of randomized controlled trials testing multi-domain interventions in headache populations. The clinical scenarios are composite illustrations, not case reports from controlled studies. Prospective trials comparing individualized domain-targeted protocols with standard care are needed.

9. Conclusion

Neck pain and headache are treated as separate diagnostic categories requiring separate interventions, yet they share neuroanatomy through the trigeminocervical complex, share upstream biological drivers across metabolic, inflammatory, hormonal, microbiome, and vascular domains, and show the same pattern of limited, partial response to single-pathway treatments that characterizes multi-domain disorders. Cellular systems theory provides a unifying framework for understanding why the cervical disc degenerates, why the trigeminal system becomes sensitized, why the migraine chronifies, and why conventional treatments provide temporary or partial relief. By identifying and addressing the biological domains driving both conditions in each individual patient, cellular systems analysis offers a path toward more durable outcomes. Emerging peptide therapeutics targeting metabolic, neuroinflammatory, gut-immune, and tissue repair pathways warrant prospective clinical investigation in combined neck pain and headache populations.

Author Information

Ty Thomas, MD, is CEO and Medical Director of Alabama Pain Physicians, a board-certified interventional pain practice in Birmingham and Bessemer, Alabama. Dr. Thomas is board-certified in Physical Medicine and Rehabilitation with additional certification in Venous and Lymphatic Medicine. Alabama Pain Physicians integrates functional laboratory assessment and metabolic optimization with conventional pain management. Contact: 205.332.3160. BamaPain.com.

Disclosures: The author reports no external conflicts of interest relevant to this manuscript. Alabama Pain Physicians offers the laboratory panels and peptide therapeutics described in this review as clinical services. No external funding was received for this work.

References

1. GBD 2021 Neck Pain Collaborators. Global, regional, and national burden of neck pain, 1990–2020, and projections to 2050. Lancet Rheumatology. 2024;6(3):e142-e155.

2. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z. Migraine remains second among the world’s causes of disability, and first among young women. J Headache Pain. 2020;21(1):137.

3. Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States. Headache. 2018;58(4):496-505.

4. Dieleman JL, Cao J, Chapin A, et al. US health care spending by payer and health condition, 1996–2016. JAMA. 2020;323(9):863-884.

5. Ashina M. Migraine. N Engl J Med. 2020;383(19):1866-1876.

6. Bogduk N. Cervicogenic headache: anatomic basis and pathophysiologic mechanisms. Curr Pain Headache Rep. 2001;5(4):382-386.

7. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;(6):CD010610.

8. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;(6):CD010611.

9. Barbanti P, Aurilia C, Egeo G, et al. Ultra-late response to anti-CGRP monoclonal antibodies in migraine. J Neurol. 2024;271:2434-2443.

10. Holzer P, Holzer-Petsche U. Constipation caused by anti-CGRP migraine therapeutics. Front Physiol. 2021;12:820006.

11. Westergaard ML, Hansen EH, Glumer C, Olesen J, Jensen RH. Definitions of medication-overuse headache in population-based studies. Cephalalgia. 2014;34(6):409-425.

12. Brinjikji W, Luetmer PH, Comstock B, et al. Systematic review of imaging features of spinal degeneration in asymptomatic populations. AJNR. 2015;36(4):811-816.

13. Gruber HJ, Bernecker C, Pailer S, et al. Hyperinsulinaemia in migraineurs is associated with nitric oxide stress. Cephalalgia. 2010;30(5):593-598.

14. Bhoi SK, Kalita J, Misra UK. Metabolic syndrome and insulin resistance in migraine. J Headache Pain. 2012;13(4):321-326.

15. Fava A, Pirritano D, Consoli D, et al. Chronic migraine in women is associated with insulin resistance. Eur J Neurol. 2014;21(2):267-272.

16. Cavestro C, et al. Migraine, brain glucose metabolism and the neuroenergetic hypothesis. J Pain. 2022;23(5):S2-S15.

17. Niederberger E, Geisslinger G. The IKK-NF-κB pathway. FASEB Journal. 2008;22(10):3432-3442.

18. Teraguchi M, Yoshimura N, Hashizume H, et al. Metabolic syndrome components and intervertebral disc degeneration: the Wakayama Spine Study. PLoS One. 2016;11(2):e0147565.

19. Zhai X, Sun C, Rong P, et al. Chronic pain and insulin resistance. Journal of Pain. 2016;17:404-413.

20. Perini F, D’Andrea G, Galloni E, et al. Plasma cytokine levels in migraineurs and controls. Headache. 2005;45(7):926-931.

21. Woolf CJ. Central sensitization. Pain. 2011;152(3 Suppl):S2-S15.

22. Watkins LR, Maier SF. Immune and glial cells in pathological pain. Physiological Reviews. 2002;82(4):981-1011.

23. MacGregor EA. Menstrual migraine and estrogen. Nat Rev Neurol. 2012;8(2):73-83.

24. Finan PH, Goodin BR, Smith MT. Sleep and pain association. Journal of Pain. 2013;14(12):1539-1552.

25. Choy EH. Sleep in pain and fibromyalgia. Nature Reviews Rheumatology. 2015;11(9):513-520.

26. Heim C, Ehlert U, Hellhammer DH. Hypocortisolism in stress-related disorders. Psychoneuroendocrinology. 2000;25(1):1-35.

27. Camilleri M. Leaky gut: mechanisms and implications. Gut. 2019;68(8):1516-1526.

28. Gross EC, Lisicki M, Fischer D, et al. The metabolic face of migraine. Cephalalgia. 2019;39(13):1631-1636.

29. Vanmolkot FH, de Haan J. Migraine and endothelial function. Cephalalgia. 2007;27(7):781-787.

30. Cohen SP, Hooten WM. Advances in the diagnosis and management of neck pain. BMJ. 2017;358:j3221.

31. Lee C, et al. MOTS-c promotes metabolic homeostasis. Cell Metabolism. 2015;21(3):443-454.

32. Gwyer D, et al. BPC 157 in musculoskeletal healing. Cell and Tissue Research. 2019;377(2):153-159.

33. Gjurasin M, et al. BPC 157 in traumatic nerve injury. Regulatory Peptides. 2010;160(1-3):33-41.

34. Zozulia AA, et al. Selank in generalized anxiety. Zh Nevrol Psikhiatr. 2008;108(4):38-48.

35. Kasian A, et al. Selank and GABAergic neurotransmission. Frontiers in Pharmacology. 2017;8:89.

36. Pickart L, Margolina A. GHK and DNA: resetting the genome. BioMed Research International. 2014;2014:151479.

37. Pickart L, et al. GHK-Cu regenerative actions. International Journal of Molecular Sciences. 2018;19(7):1987.

38. Malinda KM, et al. Thymosin beta4 in wound healing. Journal of Investigative Dermatology. 1999;113(3):364-368.

39. Szeto HH. Cardiolipin-protective compound for mitochondrial bioenergetics. British Journal of Pharmacology. 2014;171(8):2029-2050.

40. Birk AV, et al. SS-31 re-energizes mitochondria via cardiolipin. JASN. 2013;24(8):1250-1261.

41. Karaa A, et al. Elamipretide trial in mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221.

42. Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration. Nature Reviews Rheumatology. 2014;10(1):44-56.

43. Minerbi A, et al. Altered microbiome in fibromyalgia. Pain. 2019;160(11):2589-2602.

44. Helde-Frankling M, Bjorkhem-Bergman L. Vitamin D in pain management. IJMS. 2017;18(10):2170.

© 2026 Alabama Pain Physicians. All rights reserved.